Aurinia Pharmaceuticals Inc. (AUPH) Q4 2024 Earnings Call

Concluded Feb 27, 2025

Feb 27, 2025 0 turns

Period: FY2024 Q4
Runtime: —
Sources: 2 artifacts

8-K 10-K

Executive readout · one minute

Webcast research workspace

Read the call alongside every captured source. 8-K earnings release, 10-K stay in one workspace.

AUR200 pipeline development 35 2025 financial guidance 26 LUPKYNIS revenue growth 26 Discontinuation of patient-level metrics (PSS) 7 Cash flow and balance sheet 6 Operational restructuring 6

Management tone

Confident

Net tone +72 · low hedging

Grounding quotes

“With our strong 36% sales growth for LUPKYNIS in 2024, we are poised for continued success”
“We're very pleased to start 2025 in a solid position with a highly efficient organization focused on LUPKYNIS growth”
“We're excited to have grown the product more than 35% this year in 2024”
“I think there's plenty of time ahead where these guidelines, along with the EULAR and KDIGO guidelines, will be very positive for the LN market going forward and our product”

Research coverage

2 live sources

Open each available source without leaving this research workspace.

Revenue $59.87M +32.8% YoY

Diluted EPS $0.01

Net income $1.43M

Research materials

Open the source you need; every reader stays inside this workspace.

8-K earnings release Filed Feb 27, 2025 10-K report Filed Feb 27, 2025

Quarter detail

How the reported period landed and where the business moved.

Capital returned

Buybacks · derived: $21.80M

Read transcripts like this one from Claude, ChatGPT or your own code with the earnings call transcript API →